Asset profile
TDM-180935
Small molecule
Evidence outlook · lead readout
NCT06363461 · Atopic Dermatitis
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT06363461: The study was randomized, double-blinded for participants and outcome assessors, and placebo-controlled, with change in the clinical m-EASI score as its primary endpoint. However, only 24 participants were enrolled and no primary endpoint results are available, so the trial provides limited evidence at this time.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
64 competitors in this universe: 1 direct rival (same mechanism and indication), 3 same-class, 60 same-indication; 38 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| TDM-180935: this drug | Phase 2 | Small molecule | TYK2/JAK1 | ||
| ICP-332 | Phase 3 | Small molecule | TYK2/JAK1 | ||
| Brepocitinib (Lisraya) | Approved | Small molecule | TYK2/JAK1 | ||
| TLL-018 | Phase 3 | Small molecule | TYK2/JAK1 | ||
| BHV-8000 | Phase 2/3 | Small molecule | TYK2/JAK1 | ||
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Crisaborole (Eucrisa) | Approved | Small molecule | PDE4 | ||
| Difamilast (Moizerto / Adquey) | Approved | Small molecule | PDE4 | ||
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | ||
| Lebrikizumab (Ebglyss) | Approved | Monoclonal antibody | IL-13 | ||
| Nemolizumab (Nemluvio) | Approved | Monoclonal antibody | IL-31 receptor A | ||
| Roflumilast (Zoryve) | Approved | Small molecule | PDE4 | ||
| Ruxolitinib | Approved | Small molecule | JAK1/2 | ||
| Tapinarof | Approved | Small molecule | Aryl hydrocarbon receptor, Aryl Hydrocarbon Receptor Agonist | ||
| Tralokinumab (Adbry) | Approved | Monoclonal antibody | IL-13 |
…and 49 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.